Ortiz Genaro Gabriel, Moráles-Sánchez E W, Pacheco-Moisés F P, Jiménez-Gil F J, Macías-Islas M A, Mireles-Ramírez M A, González-Usigli H
Laboratorio de Desarrollo-Envejecimiento, Enfermedades Neurodegenerativas, División de Neurociencias, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, México.
Centro Universitario de Tonalá, Universidad de Guadalajara, México.
Gac Med Mex. 2017;153(Supl. 2):S72-S81. doi: 10.24875/GMM.M000008.
To determine the effect of melatonin (MEL) administration on ciclooxigenase 2 (COX-2) activity and serum concentration of nitric oxide metabolites, lipoperoxides and glutathione peroxidase (GPx) activity in patients with Parkinson's disease.
Prospective double-blind randomized clinical pilot trial. 13 patients were included and two groups were formed: MEL at doses of 25 mg orally every 12 hours for 12 months and placebo with corn starch. Patients were assessed using the Unified Parkinson's Disease Scale. A blood sample was taken at baseline and every 3 months until 12 months.
COX-2 activity decreased as did nitrates/nitrites (3, 6 and 9 months) and lipoperoxides (9 and 12 months); GPx exhibited no significant differences.
确定褪黑素（MEL）给药对帕金森病患者环氧化酶2（COX-2）活性、一氧化氮代谢产物血清浓度、脂质过氧化物以及谷胱甘肽过氧化物酶（GPx）活性的影响。
前瞻性双盲随机临床试验。纳入13名患者，分为两组：一组每12小时口服25毫克MEL，共12个月；另一组服用玉米淀粉安慰剂。使用统一帕金森病评定量表对患者进行评估。在基线时以及每3个月采集一次血样，直至12个月。
COX-2活性降低，硝酸盐/亚硝酸盐（3、6和9个月）以及脂质过氧化物（9和12个月）也降低；GPx无显著差异。
